Rebecca Dent

10PUBLICATIONS
100CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 23, 2026
Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study.

Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso-Sousa

|Jul 21, 2025
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.

Luca Licata, Marco Mariani, Giulia Viale

|Jul 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira

|Jun 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.

Rebecca Dent, Javier Cortés, Lajos Pusztai

|Jan 18, 2024
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.

Tira J Tan, Sarah Sammons, Young-Hyuck Im

|Dec 07, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Peter Schmid, Nicholas C Turner, Carlos H Barrios

Pageof 2

Frequent Collaborators

4 joint publications

Sung-Bae Kim

2 joint publications

Mafalda Oliveira

2 joint publications

Carlos H Barrios

2 joint publications

Joyce O'Shaughnessy